<DOC>
	<DOC>NCT00386191</DOC>
	<brief_summary>The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.</brief_summary>
	<brief_title>Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients with an episode of cerebral infarction (excluding cardiogenic cerebral thromboembolism) occurring at least 8 days prior to randomization and for whom the clinical course up to randomization is welldocumented Patients with a cerebral infarct confirmed by Computed Tomography or Magnetic Resonance Image Body weight : &gt; 50 kg Patients with cardiogenic cerebral thromboembolism or disease that could precipitate cardiogenic cerebral thromboembolism, such as atrial fibrillation or valvular hear disease (including valve replacement) Patients with Transient Ischemic Attack occuring after the last episode of cerebral infarction Patients with serious impairment that would hinder detection of new ischemic event Patients with bleeding diathesis, coagulopathy, or hemorrhagic disease Patients with history of intracranial hemorrhage Patients with diabetic retinopathy Hypertensive patients with a persistent increase of blood pressure.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Ischemic cerebrovascular disease</keyword>
</DOC>